Also from this source

You just read:

TREVENTIS Corporation pre clinical candidate TRV 101 demonstrates significant reduction in both amyloid beta and tau toxic aggregates in animal models of Alzheimer's disease

News provided by

TREVENTIS Corporation

Jul 20, 2015, 08:22 ET